107 results
Page 3 of 6
6-K
EX-99.1
ug6efzke3k
5 Jan 22
Current report (foreign)
7:30am
6-K
EX-99.2
n25729 1lqcmkmyw6
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.1
5jqqcjd172rhvta
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.1
svp 23hwrmycz2
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.3
w4xfpbjelcpwpmd
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
14l ggn1qhe6piwii7
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
qrayfpuxcdu8 nmn
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am
6-K
EX-99.1
38ffe11lwa o02zzwj
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am
6-K
EX-99.1
4j54gt4
12 Oct 21
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
7:30am
6-K
EX-99
3t0p7adsi
10 Aug 21
Current report (foreign)
7:31am
6-K
EX-99.1
cpx3jb
10 Aug 21
InflaRx Announces Positive Data from Second Interim Analysis
7:30am
6-K
EX-99.2
zj0s cyuefkgp48
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
enxmiurzu3cpzq6m9n8
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.3
323od4
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
ldmtz4fxc4lw36
8 Jun 21
Current report (foreign)
7:30am
6-K
EX-99.2
4nb j7s2f1gicwt
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.3
7hhzelvxxf ur
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
7nvlyz6di2uomlvdo9x0
11 May 21
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
4:30pm
6-K
EX-99.1
rr6r2
3 May 21
Current report (foreign)
4:15pm
6-K
EX-99.1
kbqod
15 Apr 21
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study
7:30am